USPTO Examiner ASAN ALPARSLAN NMN - Art Unit 1613

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18979375Coffee Bean Compositions Comprising Paraxanthine and Methods for Their ProductionDecember 2024February 2025Allow200NoNo
18737162ODOR CONTROL COMPOSITION CONCENTRATESJune 2024March 2025Allow911YesNo
18436814Method for Synthesizing Selenium Nanoparticles from Edible MushroomsFebruary 2024April 2025Abandon1420NoNo
18436404Method for Synthesizing Selenium Nanoparticles from Edible MushroomsFebruary 2024March 2025Abandon1320NoNo
18412318COMPOSITIONS AND METHODS FOR THEIR PRODUCTIONJanuary 2024September 2024Allow810NoNo
18508748IMAC-ENRICHED MICROALGAL CULTURE SUPERNATANT AND USES THEREOFNovember 2023December 2024Allow1310NoNo
185026842-BENZO-[3,4-B]QUINOLINO-[B,G]INDENO[1',2':3,4]FLUORENO-[1,2-D]OXONINE-24-CHLORO-5,11,16,21-TETRAONE AS AN ANTIMICROBIAL COMPOUNDNovember 2023January 2024Allow200NoNo
18371084Method for Synthesizing Selenium Nanoparticles from Edible MushroomsSeptember 2023May 2025Abandon2031NoNo
18454753Method for Manufacturing a Calcified Tissue SubstituteAugust 2023March 2025Allow1910NoNo
18234938Skin Care Composition and Method of Using the SameAugust 2023December 2024Abandon1610NoNo
18303694BROMIDE SOURCE FOR USE IN TREATING AUTISM SPECTRAL DISORDERApril 2023March 2024Allow1010NoNo
18136350APPLICATION OF A HYDROGEL IN THE PREPARATION OF PRODUCTS FOR THE TREATMENT OF BACTERIAL INFECTIONSApril 2023February 2024Allow1010NoNo
18249274FORMULATION AND NONCOVALENT STABILIZATION OF OLIVETOLIC ACID DERIVATIVESApril 2023April 2025Allow2421YesNo
18299323COMPOSITIONS AND METHODS FOR THEIR PRODUCTIONApril 2023November 2023Allow710YesNo
18175573STABILIZED ACTIVE OXYGEN-GENERATING ANTISEPTIC COMPOSITIONS, IRRIGATION SOLUTIONS, AND ARTICLESFebruary 2023January 2024Abandon1010NoNo
17979490NOVEL IRON COMPOSITIONS AND METHODS OF MAKING AND USING THE SAMENovember 2022February 2023Allow300NoNo
17966361Hair Cosmetic Composition Comprising Silicones And Surfactants, And Cosmetic Treatment ProcessOctober 2022December 2023Allow1410NoNo
17937327CBD FORMULATIONS AND USES THEREOFSeptember 2022December 2024Abandon2610NoNo
17878324HONEY/SURFACTANT COMBINATIONS FOR WOUND TREATMENTAugust 2022January 2024Abandon1810NoNo
17836617COMPOSITIONS AND METHODS FOR NASAL ADMINISTRATION OF DRUGS TO BRAIN AND FOR SYSTEMIC EFFECTJune 2022April 2024Allow2210NoNo
17836751PHYTOTHERAPY COMPOSITION ASSOCIATED WITH POLYVITAMIN AND MINERAL SUPPLEMENTSJune 2022December 2023Abandon1910NoNo
17739103CBD FORMULATIONS AND USES THEREOFMay 2022December 2024Abandon3110NoNo
17726843USE OF LACTIC ACID BACTERIA OR FERMENTATION PRODUCT THEREOF FOR MAINTAINING OR IMPROVING GASTROINTESTINAL CONDITIONApril 2022April 2024Allow2420NoNo
17716694STABLE EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF CLOZAPINEApril 2022November 2023Allow1940YesNo
17651363STABILIZED ACTIVE OXYGEN-GENERATING ANTISEPTIC COMPOSITIONS, IRRIGATION SOLUTIONS, AND ARTICLESFebruary 2022February 2023Allow1231YesNo
17672072NOVEL IRON COMPOSITIONS AND METHODS OF MAKING AND USING THE SAMEFebruary 2022July 2023Allow1710NoNo
17589034PERFORMANCE ENHANCING BEVERAGEJanuary 2022January 2024Abandon2310NoNo
17584502ANTIMICROBIAL AND CLEANSING COMPOSITIONJanuary 2022February 2024Abandon2511NoNo
17575276METHOD OF PREVENTING COVID-19 INFECTIONJanuary 2022December 2024Abandon3560YesNo
17572034MATERIALS AND METHODS FOR ENHANCING BONE CELL DIFFERENTIATIONJanuary 2022December 2023Abandon2301NoNo
17572286COMPOSITIONS AND METHODS OF TREATMENT OF CHRONIC INFECTIOUS DISEASESJanuary 2022December 2023Abandon2301NoNo
17567759DRUG DELIVERY COMPOSITION AND A METHOD OF ADMINISTERING THE DRUGJanuary 2022December 2022Abandon1110NoNo
17547624THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSESDecember 2021June 2023Allow1821YesNo
17484916MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSSeptember 2021August 2022Abandon1120NoNo
17373781ANHYDROUS ANTIMICROBIAL TOPICAL FORMULATIONS AND METHODS OF USE THEREOFJuly 2021June 2024Allow3520YesNo
17367577COSMETIC COMPOSITION INCLUDING MICROSPHERES CONTAINING HIGH CONCENTRATION OF OXYGEN AND METHOD OF PREPARING THE SAMEJuly 2021December 2023Abandon3020NoNo
17335193ANTIOXIDANT, SKIN-WHITENING AND WRINKLE-REDUCING MULTIFUNCTIONAL COSMETIC COMPOSITION CONTAINING FERMENTED RICE BY-PRODUCT EXTRACT OR FRACTION THEREOF AS ACTIVE INGREDIENTJune 2021March 2025Abandon4640NoNo
17298659COMPOSITIONS FOR WEIGHT MANAGEMENTMay 2021January 2025Allow4321NoNo
17327308STABLE PARENTERAL COMPOSITION OF LACOSAMIDEMay 2021February 2022Allow821NoNo
17322299MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSMay 2021March 2023Abandon2230YesYes
17294586USE OF POLYETHYLENE GLYCOL FOR THE CONTROL OF PLANT-DAMAGING INSECTS AND ACARIMay 2021September 2024Abandon4010NoNo
17290919WATER-SOLUBLE EFFERVESCENT SOLID PERFUMEMay 2021December 2024Abandon4320NoNo
17288873ACTIVE SUBSTANCE COMPOSITION FOR MODIFYING HAIR SURFACE AND CHANGING THE SHAPE OF HAIRApril 2021March 2025Abandon4721NoNo
17282832A METHOD FOR FIGHTING FEMALE BODY ODORSApril 2021May 2024Abandon3820NoNo
17218773METHODS AND COMPOSITIONS FOR IMPROVING SKINMarch 2021March 2024Allow3531YesNo
17217020SILICONE OIL FREE ANTIPERSPIRANTSMarch 2021March 2024Abandon3520NoNo
17274073POLYMER CONJUGATE BONDED TO TERTIARY AMINE COMPOUND OR IMINE COMPOUND AND PRODUCTION METHOD THEREFORMarch 2021September 2024Abandon4301NoNo
17273141Flat Product for Microbiological Sanitation of the Urogenital TractMarch 2021April 2024Abandon3821NoNo
17270539COMPOSITIONS AND METHODS FOR THE TREATMENT OF MASTITISFebruary 2021April 2025Abandon5041YesNo
17174054DEUTERATED POLYUNSATURATED FATTY ACIDS OR ESTERS THEREOF FOR COSMETIC APPLICATIONSFebruary 2021May 2025Abandon5131NoYes
17168098FLECAINIDE COMBINATION AND CONTROLLED-RELEASE FORMULATIONS FOR TREATING HEART DISEASESFebruary 2021March 2022Abandon1320NoNo
17262563TOPICAL EMULSION OF AN ANTICHOLINERGIC COMPOUNDJanuary 2021July 2024Abandon4230NoNo
17155327Skin Care Composition and Method of Using the SameJanuary 2021July 2023Allow2911YesNo
17257769MIXTURES OF BRANCHED CHAIN KETO ACIDS (BCKA) AND METHOD FOR THE PRODUCTION OF SUCH MIXTURESJanuary 2021January 2023Allow2410NoNo
17132948ANTIPERSPIRANT COSMETIC PRODUCT WITHOUT CYCLIC SILICONE OILSDecember 2020January 2023Abandon2520NoNo
17255532STABLE LYOPHILIZED DOSAGE FORM OF PROTEINDecember 2020June 2024Abandon4210NoNo
17058224Anti-Adhesive Shear Thinning HydrogelsNovember 2020June 2023Abandon3111NoNo
17057814COMPOUNDS FOR PREVENTING AND TREATING SKIN OR MUCOSAL AFFECTIONS HAVING AN INFLAMMATORY COMPONENTNovember 2020May 2023Allow3021NoNo
17053471IMAC-ENRICHED MICROALGAL CULTURE SUPERNATANT AND USES THEREOFNovember 2020August 2023Allow3321NoNo
17072005Interactional BiosystemOctober 2020June 2023Abandon3211NoNo
17047264USE OF SPECIFIC BENZYLIDENE MALONATES FOR PROTECTING THE SKIN FROM CHEMICALLY INDUCED STRESSOctober 2020February 2023Abandon2820NoNo
15733704Siloxanes for treating textiles and for use in cleaning and care formulationsSeptember 2020March 2025Allow5321YesNo
16982529A COMPOSITION FOR USE IN THE TREATMENT OF CONDITIONS CAUSED BY CALCIUM DEFICIENCYSeptember 2020October 2022Allow2511YesNo
16981578NANODIAMONDS AS ARTIFICIAL PROTEINS FOR REGULATION OF A CELL SIGNALLING SYSTEMSeptember 2020May 2023Allow3230NoNo
16977231TOPICAL COMPOSITIONSeptember 2020February 2024Allow4241NoNo
16975807METHYLPHENIDATE-CONTAINING PATCHAugust 2020April 2023Abandon3221NoNo
16987941CBD FORMULATIONS AND USES THEREOFAugust 2020October 2022Abandon2611NoNo
16987103CONSUMABLE COMPOSITIONS AND METHODS OF PRODUCING THE SAMEAugust 2020March 2023Allow3140YesNo
16934526METHOD OF REMOTELY CONTROLLING PAINJuly 2020July 2025Allow5980NoNo
16919856METHOD TO PREPARE PHARMACEUTICAL COMPOSITIONS OF SUGAMMADEXJuly 2020January 2022Allow1820YesNo
16915734ANTI-AGING COMPOSITIONS AND SKIN MASKS CONTAINING ANTI-AGING COMPOSITIONSJune 2020September 2023Allow3960NoYes
16914460COSMETIC COMPOSITION INCLUDING MICROSPHERES CONTAINING HIGH CONCENTRATION OF OXYGEN AND METHOD OF PREPARING THE SAMEJune 2020October 2021Abandon1620NoNo
16913046COMPOSITIONS AND METHODS TO TREAT DISEASEJune 2020March 2022Allow2021YesNo
16912876DISSOLVABLE SOLID FIBROUS ARTICLES CONTAINING ANIONIC SURFACTANTSJune 2020April 2023Allow3450YesNo
16909591EYE DROP FORMULATION AND METHOD FOR SUSTAINED DELIVERY OF MEDICAMENT TO THE RETINAJune 2020August 2022Allow2531YesNo
16904364METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBESJune 2020July 2021Allow1311YesNo
16901233SURFACTANT-FREE COSMETIC COMPOSITIONJune 2020September 2021Allow1530YesNo
16772776FRIGOSTABLE COMPOSITION FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF A TRIPTAN COMPOUNDJune 2020May 2022Allow2330YesNo
16897927TOPICAL TREATMENT OF VITILIGO BY A JAK INHIBITORJune 2020November 2021Abandon1710NoNo
16770730PROPANEDIOL MONOACETATE MONONITRATEJune 2020December 2021Allow1800YesNo
16770374LIPID EMULSIFIED DRUG DELIVERY SYSTEMS FOR CHEMOPREVENTION AND TREATMENTJune 2020November 2022Allow2921YesYes
16770011COMPOSITION BASED ON PROBIOTICS AND USES THEREOFJune 2020August 2022Allow2711NoNo
16891178RECOVERY DIETARY SUPPLEMENTJune 2020January 2023Allow3231YesNo
16887243SOLID COSMETIC HAIR CONDITIONING AGENTS (FOAMS)May 2020May 2021Allow1111YesNo
16760941COATED AGROCHEMICAL COMPOSITIONMay 2020November 2023Allow4221NoNo
16864734CLEANSING AND CONDITIONING TABLETS, COMPOSITIONS, AND METHODS OF MANUFACTURE THEREOFMay 2020August 2021Abandon1511NoNo
16865263ZINC PICOLINATE, MAGNESIUM PICOLINATE AND SELENIUM METHIONINE COMPOSITIONS AND METHODS OF USEMay 2020February 2022Abandon2220NoNo
16852133CANNABINOID LOZENGE FORMULATIONApril 2020October 2021Allow1830YesNo
16755692COSMETIC COMPOSITION CONTAINING NICOTINAMIDE MONONUCLEOTIDEApril 2020June 2022Abandon2620NoNo
16846383METHOD FOR FORMING A NATURAL HAIR CONDITIONING COMPOSITIONApril 2020April 2021Abandon1210NoNo
16833593Composition of Athletic and Fitness Supplements, Method for Production and Method for Pulmonary Administration of SameMarch 2020June 2021Abandon1511NoNo
16647135SKIN WHITENING COMPOSITION COMPRISING CULTURED PRODUCT OF BACILLUS HWAJINPOENSIS OR EXTRACT THEREOFMarch 2020March 2022Allow2420NoNo
16645860ANTIOXIDANT, SKIN-WHITENING AND WRINKLE-REDUCING MULTIFUNCTIONAL COSMETIC COMPOSITION CONTAINING FERMENTED RICE BY-PRODUCT EXTRACT OR FRACTION THEREOF AS ACTIVE INGREDIENTMarch 2020September 2021Abandon1810NoNo
16645878COMPOSITIONS COMPRISING LESPEDEZA PLANT EXTRACTMarch 2020August 2024Abandon5360NoNo
16814163COMPOSITIONS AND METHODS FOR NASAL ADMINISTRATION OF DRUGS TO BRAIN AND FOR SYSTEMIC EFFECTMarch 2020March 2022Allow2421YesNo
16644101COSMETIC COMPOSITION COMPRISING DENDROBIUM CANDIDUM FLOWER EXTRACTMarch 2020November 2022Abandon3220YesYes
16805223NOVEL IRON COMPOSITIONS AND METHODS OF MAKING AND USING THE SAMEFebruary 2020November 2021Allow2030YesNo
16642999WATER BASED CONCENTRATED PRODUCT FORMS OF OIL-SOLUBLE ORGANIC UV ABSORBERSFebruary 2020October 2023Allow4431YesNo
16642557COMPOSITIONS AND METHODS FOR INCREASING BUTYRATE PRODUCTIONFebruary 2020November 2023Allow4441YesNo
16641709A PERSONAL CARE COMPOSITIONFebruary 2020June 2022Allow2721NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ASAN, ALPARSLAN NMN.

Strategic Value of Filing an Appeal

Total Appeal Filings
8
Allowed After Appeal Filing
2
(25.0%)
Not Allowed After Appeal Filing
6
(75.0%)
Filing Benefit Percentile
30.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ASAN, ALPARSLAN NMN - Prosecution Strategy Guide

Executive Summary

Examiner ASAN, ALPARSLAN NMN works in Art Unit 1613 and has examined 132 patent applications in our dataset. With an allowance rate of 50.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 29 months.

Allowance Patterns

Examiner ASAN, ALPARSLAN NMN's allowance rate of 50.8% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ASAN, ALPARSLAN NMN receive 2.21 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ASAN, ALPARSLAN NMN is 29 months. This places the examiner in the 44% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +51.1% benefit to allowance rate for applications examined by ASAN, ALPARSLAN NMN. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 23.7% of applications are subsequently allowed. This success rate is in the 24% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 29.5% of cases where such amendments are filed. This entry rate is in the 34% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 25.0% are granted (fully or in part). This grant rate is in the 15% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.